CSTL Castle Biosciences Inc

Price (delayed)

$73.46

Market cap

$1.84B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.73

Enterprise value

$1.43B

Highlights
The debt has shrunk by 100% YoY
Castle Biosciences's quick ratio has increased by 18% QoQ
CSTL's EPS has dropped by 78% year-on-year and by 35% since the previous quarter
The net income has declined by 47% since the previous quarter

Key stats

What are the main financial stats of CSTL
Market
Shares outstanding
25.06M
Market cap
$1.84B
Enterprise value
$1.43B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
4.38
Price to sales (P/S)
26.89
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
21.07
Earnings
Revenue
$68.04M
EBIT
-$13.18M
EBITDA
-$12.57M
Free cash flow
$1.49M
Per share
EPS
-$0.73
Free cash flow per share
$0.06
Book value per share
$16.76
Revenue per share
$2.73
TBVPS
$17.56
Balance sheet
Total assets
$437.33M
Total liabilities
$18.75M
Debt
$0
Equity
$418.59M
Working capital
$409.09M
Liquidity
Debt to equity
0
Current ratio
24.27
Quick ratio
24.03
Net debt/EBITDA
32.39
Margins
EBITDA margin
-18.5%
Gross margin
84.8%
Net margin
-22.2%
Operating margin
-17.4%
Efficiency
Return on assets
-4.7%
Return on equity
-5.2%
Return on invested capital
-89%
Return on capital employed
-3.1%
Return on sales
-19.4%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CSTL stock price

How has the Castle Biosciences stock price performed over time
Intraday
-3.47%
1 week
2.18%
1 month
24.76%
1 year
71.04%
YTD
9.4%
QTD
7.3%

Financial performance

How have Castle Biosciences's revenue and profit performed over time
Revenue
$68.04M
Gross profit
$57.72M
Operating income
-$11.86M
Net income
-$15.13M
Gross margin
84.8%
Net margin
-22.2%
The operating income has plunged by 81% from the previous quarter
The operating margin has dropped by 67% since the previous quarter
The net income has declined by 47% since the previous quarter
The net margin has decreased by 35% QoQ

Growth

What is Castle Biosciences's growth rate over time

Valuation

What is Castle Biosciences stock price valuation
P/E
N/A
P/B
4.38
P/S
26.89
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
21.07
CSTL's EPS has dropped by 78% year-on-year and by 35% since the previous quarter
The P/S is 49% above the last 4 quarters average of 18.1
CSTL's revenue is up by 12% YoY and by 9% from the previous quarter

Efficiency

How efficient is Castle Biosciences business performance
Castle Biosciences's return on assets has shrunk by 177% YoY and by 12% QoQ
The ROE has shrunk by 145% YoY and by 4% QoQ
Castle Biosciences's return on invested capital has shrunk by 130% QoQ
CSTL's return on sales has dropped by 60% since the previous quarter

Dividends

What is CSTL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CSTL.

Financial health

How did Castle Biosciences financials performed over time
The total liabilities has declined by 42% year-on-year and by 21% since the previous quarter
CSTL's current ratio is up by 18% since the previous quarter
The debt is 100% lower than the equity
The debt has shrunk by 100% YoY
CSTL's debt to equity has dropped by 100% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.